Applied DNA Sciences Sells Certainty Business for $10M
Ticker: BNBX · Form: 8-K · Filed: Jun 28, 2024 · CIK: 744452
Sentiment: neutral
Topics: divestiture, sale, strategic-shift
Related Tickers: APDN
TL;DR
APDN selling Certainty biz to Gores Group for $10M cash to focus on core DNA tech.
AI Summary
Applied DNA Sciences, Inc. announced on June 27, 2024, that it has entered into a definitive agreement to sell its Certainty business to an affiliate of the Gores Group for $10 million in cash. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. This divestiture is part of Applied DNA Sciences' strategy to focus on its core DNA-based technologies.
Why It Matters
This sale allows Applied DNA Sciences to streamline its operations and concentrate on its core DNA-based technologies, potentially leading to improved financial performance and strategic focus.
Risk Assessment
Risk Level: medium — The sale price is a significant portion of the company's market cap, and the success of the divestiture and future focus are key to its valuation.
Key Numbers
- $10.0M — Sale Price (Cash received for the Certainty business.)
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — Seller
- Gores Group (company) — Buyer
- $10 million (dollar_amount) — Sale price
- June 27, 2024 (date) — Agreement date
- third quarter of 2024 (date) — Expected closing
FAQ
What is the specific business being sold?
The filing indicates that Applied DNA Sciences is selling its 'Certainty' business.
Who is the buyer of the Certainty business?
The buyer is an affiliate of The Gores Group.
What is the total cash consideration for the sale?
The definitive agreement is for $10 million in cash.
When is the transaction expected to close?
The transaction is expected to close in the third quarter of 2024.
What is the strategic rationale for this sale?
The divestiture is part of Applied DNA Sciences' strategy to focus on its core DNA-based technologies.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-28 16:30:49
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
- $2.5 million — intain stockholders' equity of at least $2.5 million (the "Stockholders' Equity Requirement"
Filing Documents
- tm2418539d1_8k.htm (8-K) — 26KB
- 0001104659-24-076311.txt ( ) — 193KB
- apdn-20240627.xsd (EX-101.SCH) — 3KB
- apdn-20240627_lab.xml (EX-101.LAB) — 33KB
- apdn-20240627_pre.xml (EX-101.PRE) — 22KB
- tm2418539d1_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On June 27, 2024, Applied DNA Sciences, Inc. (the "Company") received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that, based on the information contained in the Company's Form 8-K, dated June 18, 2024, the Company complies with Nasdaq Listing Rule 5550(b)(1), which requires issuers listed on The Nasdaq Capital Market to maintain stockholders' equity of at least $2.5 million (the "Stockholders' Equity Requirement"). If, at the time of its next periodic report, the Company does not evidence compliance with the Stockholders' Equity Requirement, the Company may be subject to delisting. At that time, Nasdaq will provide written notification to the Company, which may then appeal Nasdaq's determination to a Hearings Panel.
Financial Statements and Exhibits
Financial Statements and Exhibits. ( d) Exhibits 104 Cover Page Interactive Data File (formatted in Inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 28, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer